Subgroup analysis by sex and baseline body mass index (BMI) in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist
Authors' conclusion
In people with a BMI ≥27 kg/m2, survodutide was associated with clinically meaningful reductions in bodyweight and waist circumference when compared with placebo, in prespecified subgroups based on sex and baseline BMI, and was tolerated at all doses tested.
Study context
- Population
- People aged 18–75 years with BMI ≥27 kg/m², without diabetesrandomized 1:1:1:1:1
- Participants
- 387 people
- Comparison
- Once-weekly subcutaneous survodutide vs placebo, by sex and baseline BMI
Methodological detailsplacebo-controlled, prespecified subgroups by sex and baseline BMI, descriptive analysis, 20-week dose escalation; 26-week dose maintenance
- Placebo-controlled
- Prespecified subgroups by sex and baseline BMI
- Descriptive analysis
- 20-week dose escalation; 26-week dose maintenance
Primary result
As reported in the abstract
Bodyweight and waist circumference reductions by sex and baseline BMI · 46 weeks
- Females had greater reductions in bodyweight and waist circumference than males
- Lower baseline BMI had greater proportional bodyweight reductions than higher baseline BMI; trend reversed for waist circumference reductions
- On-treatment data or all data censored for COVID-19-related treatment discontinuations
- Full analysis set, planned treatment
Safety
Adverse events by subgroup
- AE rates comparable between subgroups for sex and baseline BMI
- Nausea was the most frequently reported gastrointestinal AE in all subgroups
Original publication
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist. Diabetes Obes Metab. Published 16 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →